New developments in lupus-associated antiphospholipid syndrome

Lupus

Volumn 17, Issue 5 SPEC. ISS., 2008, Pages 443-446

  Lockshin, M D ^a   Ronald Derksen, H W M ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; CLINICAL TRIAL; DISEASE ASSOCIATION; HUMAN; LOW DRUG DOSE; PATHOGENESIS; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ANIMALS; ANTIPHOSPHOLIPID SYNDROME; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; THROMBOSIS;

EID: 44849126725     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308090032     Document Type: Review

References (37)

1. Miyakis, S, Lockshin, MD, Atsumi, T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
2. Levine, JS, Branch, DW, Rauch, J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-763.
3. Asherson, RA, Cervera, R, de Groot, PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12: 530-534.
4. Cervera, R, Piette, JC, Font, J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-1027.
5. Bayraktar, UD, Erkan, D, Bucciarelli, S, Espinosa, G, Asherson, R. The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol 2007; 34: 346-352.
6. McClain, MT, Arbuckle, MR, Heinlen, LD, et al. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum 2004; 50: 1226-1232.
7. Erkan, D, Yazici, Y, Peterson, MG, Sammaritano, L, Lockshin, MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002; 41: 924-929.
8. Bouma, B, de Groot, PG, van den Elsen, JM, et al. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999; 18: 5166-5174.
9. Casciola-Rosen, L, Rosen, A, Petri, M, Schlissel, M. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci USA 1996; 93: 1624-1629.
10. de Laat, B, Derksen, RH. van, LM, Pennings, MT, de Groot, PG. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood 2006; 107: 1916-1924.
11. Hulstein, JJ, Lenting, PJ, de Laat, B, Derksen, RH, Fijnheer, R, de Groot, PG. beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood 2007; 110: 1483-1491.
12. Girardi, G. Heparin treatment in pregnancy loss: potential therapeutic benefits beyond anticoagulation. J Reprod Immunol 2005; 66: 45-51.
13. Salmon, JE, Girardi, G, Lockshin, MD. The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients. Nat Clin Pract Rheumatol 2007; 3: 140-147.
14. Pierangeli, SS, Girardi, G, Vega-Ostertag, M, Liu, X, Espinola, RG, Salmon, J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005; 52: 2120-2124.
15. Fleming, SD, Egan, RP, Chai, C, et al. Anti-phospholipid antibodies restore mesenteric ischemia/reperfusion-induced injury in complement receptor 2/complement receptor 1-deficient mice. J Immunol 2004; 173: 7055-7061.
16. Weitz, JI, Middeldorp, S, Geerts, W, Heit, JA. Thrombophilia and new anticoagulant drugs. Hematology Am Soc Hematol Educ Program 2004; 424-438.
17. Finazzi, G, Brancaccio, V, Moia, M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996; 100: 530-536.
18. Somers, E, Magder, LS, Petri, M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 2002; 29: 2531-2536.
19. Giron-Gonzalez, JA. Garcia del, RE, Rodriguez, C, Rodriguez-Martorell, J, Serrano, A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 2004; 31: 1560-1567.
20. Forastiero, R, Martinuzzo, M, Pombo, G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005; 3: 1231-1238.
21. Erkan, D, Harrison, MJ, Levy, R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007; 56: 2382-2391.
22. Petri, M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996; 25: 191-193.
23. Haque, S, Bruce, IN. Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease. Nat Clin Pratt Cardiovasc Med 2005; 2: 423-430.
24. Mok, CC. Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus. Scand J Rheumatol 2006; 35: 85-95.
25. Erkan, D, Lockshin, MD. Antiphospholipid syndrome. Curr Opin Rheumatol 2006; 18: 242-248.
26. Rosove, MH, Brewer, PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303-308.
27. Khamashta, MA, Cuadrado, MJ, Mujic, F, Taub, NA, Hunt, BJ, Hughes, GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-997.
28. Crowther, MA, Ginsberg, JS, Julian, J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-1138.
29. Finazzi, G, Marchioli, R, Brancaccio, V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848-853.
30. Oden, A, Fahlen, M. Oral anticoagulation and risk of death: a medical record linkage study. BMJ 2002; 325: 1073-1075.
31. Erkan, D, Lockshin, MD. How much warfarin is enough in APS related thrombosis? Thromb Res 2004; 114: 435-442.
32. Kasthuri, RS, Roubey, RAS. Warfarin and the antiphospholipid syndrome: does one size fit all? Arthritis Rheum 2007; 57: 1346-1347.
33. Levine, SR, Brey, RL, Tilley, BC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 576-584.
34. Empson, M, Lassere, M, Craig, JC, Scott, JR. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol 2002; 99: 135-144.
35. Derksen, RH, Khamashta, M, Branch, DW. Management of the obstetric antiphospholipid syndrome. Arthritis Rheum 2004; 50: 1028-1039.
36. Clowse, ME, Magder, LS, Witter, F, Petri, M. Early risk factors for pregnancy loss in lupus. Obstet Gynecol 2006; 107: 293-299.
37. Bates, SM, Greer, IA, Hirsh, J, Ginsberg, JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 627S-644S.